New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma.

[New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma]. Rev Med Interne. 2018 May 22;: Authors: Rossi C, Bastie JN Abstract In this review, we report the main advances of the last years in the four most common lymphomas in France, namely Hodgkin lymphoma, large cell diffuse B lymphoma, follicular lymphoma and mantle cell lymphoma. We have identified consensual practices in first line in France and then distinguished the targeting by new molecules. Thus, we wanted to highlight the problems for each of these four lymphomas and understand the tools used to find solutions. Finally, this review makes it possible to understand to what extent the new molecules (targeted therapies, immunotherapy) make it possible to continuously improve the management of patients with lymphomas. The global dynamics seems to reduce the place of conventional chemotherapies in favor of these new molecules. However, because of the increase in therapeutic possibilities, the challenge remains to find the combination associated with the best risk-benefit ratio. PMID: 29801709 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research

Related Links:

This study expands on earlier reports on the therapeutic potential of distinctive tumor antigen–targeting mAbs and facilitates the understanding of the mechanism and potential of ADCC by γδ T-cell subsets.
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Basic Studies Source Type: research
Authors: Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ Abstract BACKGROUND: Provider experience, or clinical volume, is associated with improved outcomes in many complex healthcare settings. Despite increased complexity of anticancer therapies, studies evaluating physician-level experience and cancer treatment outcomes are lacking. METHODS: A population-based study was conducted of older adults (aged ≥66 years) diagnosed with B-cell non-Hodgkin's lymphoma in 2004 through 2011 using SEER-Medicare data. Analysis focused on outcomes in patients receiving rituximab, the ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Abstract Patients with HIV-associated lymphocyte-depleted Hodgkin lymphoma (HIV-HL) often present with advanced, extranodal disease and aggressive clinical features, limiting definitive therapeutic intervention. Here we report two patients with HIV-HL who presented with multi-organ dysfunction as an initial manifestation of their malignancy. Both were initially treated with brentuximab vedotin (BV), which led only to a temporary partial response, highlighting the challenges of treatment. One patient was eventually started on nivolumab and responded very well to the immune checkpoint inhibitor. To our knowledge, th...
Source: Acta Haematologica - Category: Hematology Authors: Tags: Acta Haematol Source Type: research
CD19-targeted chimeric antigen receptor modified T-cell immunotherapy (CD19 CAR-T cells) has shown excellent anti-tumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [1] and non-Hodgkin lymphoma (NHL) [2,3], which led to the approval of tisagenlecleucel (Kymriah ࣨ) and axicabtagene ciloleucel (Yescartaࣨ) by regulatory agencies in the United States, Europe, Canada, Japan and Australia. This approvalhas transformed the care of patients with relapsed/refractory ALL and aggressive B cell NHL [4-6].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Authors: Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N Abstract Cancer has recently been identified as the leading cause of mortality worldwide. Several conventional treatments and cytotoxic immunotherapies have been developed and made available to the market. Considering the complex behavior of tumors and the involvement of numerous genetic and cellular factors involved in tumorigenesis and metastasis, there is a need to develop a promising immunotherapy that targets tumors at both the cellular and genetic levels. Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel therapeuti...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Publication date: Available online 2 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Avyakta Kallam, Julie M. VoseAbstractNon-Hodgkin lymphomas that are refractory to or relapse after frontline chemoimmunotherapy have a poor prognosis. Although high dose chemotherapy, followed by autologous stem cell transplantation remains the standard of care at relapse, this treatment modality leads to a cure in less than 50% of the patients. Adoptive cellular immunotherapy with anti CD 19 chimeric antigen receptor (CAR) T cell has changed the treatment landscape in B cell lymphomas. They have emerged as effective t...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsR/R LBCL is responsive to RT, although RR are lower among DHL/THL patients. Given poor survival after RT, in-field control was hard to evaluate in this cohort. Larger cohorts are required to better elucidate whether differences in response rates are driven by larger disease burden at RT versus tumor biology. These findings are of increasing pertinence in light of use of RT as bridging therapy to cellular immunotherapies.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Non-Hodgkin lymphomas that are refractory to or relapse after frontline chemoimmunotherapy have a poor prognosis. Although high dose chemotherapy, followed by autologous stem cell transplantation remains the standard of care at relapse, this treatment modality leads to a cure in less than 50% of the patients. Adoptive cellular immunotherapy with anti CD 19 chimeric antigen receptor (CAR) T cell has changed the treatment landscape in B cell lymphomas. They have emerged as effective therapy in patients with multiple relapsed/refractory disease, capable of sustaining durable remissions.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Publication date: Available online 28 September 2019Source: Practical Radiation OncologyAuthor(s): Alexandra D. Dreyfuss, Michael Lariviere, Leslie K. Ballas, John P. PlastarasAbstractCell-based immunotherapies have the potential to redefine modern oncologic care, providing promising new treatments for patients with otherwise poor prognoses. Chimeric antigen receptor (CAR) T cell therapy has produced remarkable remission rates in patients with even the most treatment-refractory hematologic malignancies. In 2018 the FDA approved two CAR-T cell therapies for relapsed/refractory aggressive non-Hodgkin lymphoma (r/rNHL). With ...
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
In this study, we reported the management of a patient with recurrent and refractory multiple myeloma and three patients with acute lymphocytic leukemia who suffered CRS during CAR-T treatment. The early application of tocilizumab, an anti-IL-6 receptor antibody, according to toxicity grading and clinical manifestation is recommended especially for patients who suffer continuous hyperpyrexia, hypotensive shock, acute respiratory failure, and whose CRS toxicities deteriorated rapidly. Moreover, low doses of dexamethasone (5 –10 mg/day) were used for refractory CRS not responding to tocilizumab. The effective managemen...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
More News: France Health | Immunotherapy | Internal Medicine | Lymphoma